TransMedics (TMDX): Can the Stock Close the Gap to the $100 Analyst Target With a +31% Move?

Key Takeaways

• The central price target of $100 is the arithmetic mean of roughly ten current, attributable analyst price targets, rounded to a clean level.
• The latest verified price is about $76.52, implying a required move of roughly 31% — a substantial but not extreme gain.
• Current analyst targets span a wide range from $65 (Stifel) to $120 (Barclays and TD Cowen), reflecting genuine disagreement about the stock's growth trajectory.
• Supporting factors include double-digit transplant procedure growth and strong expected revenue expansion; the main risks are slowing profit growth, valuation, and competitive and reimbursement uncertainty.
• The target is a research estimate, not a guarantee, and reflects a roughly 12-month horizon rather than a near-term forecast.

Analyst Price Targets and the Consensus Picture

TransMedics Group, Inc. (TMDX) develops the Organ Care System that preserves donor organs during transport for transplants. Analyst coverage remains broad yet divided. Compiling the latest attributable targets from Barclays ($120, Overweight), TD Cowen ($120, Buy), Needham ($106, Buy), Piper Sandler ($100, Overweight), Canaccord Genuity ($95, Buy), J.P. Morgan ($92, Hold), Evercore ISI ($90, Buy), UBS ($77, Hold), and Stifel ($65, Hold) yields a range of $65 to $120 with a mean near $97, which rounds neatly to the $100 central target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Ratings show real dispersion: six to eight analysts lean Buy or Overweight, four to six sit at Hold or Neutral, and at least one source remains bearish. Optimistic voices highlight rising U.S. transplant volumes and revenue momentum, while skeptics focus on fading profitability and increasing competition. Several firms have already lowered targets this year, including Piper Sandler to $100 from $120 in August, Needham to $106 from $142, and Evercore ISI to $90 from $100.

Where the Stock Stands Today and the Road to $100

After closing recently at $76.52, the shares sit well below the 52-week high of $156.00 and modestly above the 52-week low of $60.11. Closing the gap to $100 would require a gain of about 31%. Year to date the stock has dropped roughly 37%, which has compressed valuation metrics: the trailing P/E stands near 20 while the forward P/E is around 42. Consensus estimates project revenue rising about 22% in 2026 to roughly $742 million and another 18% in 2027 to near $875 million, with EPS expected to fall to about $1.51 in 2026 before recovering toward $2.25 in 2027. A move toward $100 will likely require renewed confidence that earnings growth is reaccelerating alongside revenue.

Factors That Could Help the Stock Approach the Target

The bullish thesis centers on steady demand for transplants. Data on U.S. procedures continue to show mid-teens or stronger year-over-year growth, and TransMedics leads in the still-emerging machine perfusion segment that improves on traditional cold storage. Recurring revenue from logistics, broader program adoption, and greater use of the OCS across heart, lung, and liver cases all reinforce the growth story. Stronger quarterly results or raised guidance could lift both analyst targets and the share price.

Obstacles That Could Keep the Target Out of Reach

Profitability trends and valuation remain the primary concerns. Net income declined year over year in the most recent quarter despite revenue growth, and consensus forecasts a notable EPS drop for full-year 2026. Competitive intensity, staffing limits at hospitals, reimbursement questions, and the expense of building a national logistics network could further pressure margins. At a forward P/E near 42, the valuation already embeds significant growth expectations, so any shortfall in guidance, transplant volumes, or margins could push $100 further away. The broad spread between $65 and $120 itself underscores how divided analysts remain.

Technical Levels Worth Watching

The 52-week range of $60.11 to $156.00 frames the current structure, with the price in the lower half. The $60 zone from the May 2026 low serves as key support, while $80 represents near-term resistance. Beyond that, $100 functions as both the central target and a psychological barrier; the $120 area, where several targets cluster, marks the next significant resistance and aligns with the high end of current forecasts.

Time Horizon and Key Items to Follow

Most analyst targets reflect a roughly 12-month research horizon. The next earnings release, expected in late October 2026, stands out as the nearest catalyst; investors will focus on revenue, EPS, margin trends, and any updates to guidance. Transplant-volume reports, competitive developments, target revisions, and reimbursement news will also influence whether the shares can move closer to $100.

Adding AI Daily Buy/Sell Signals to the Process

In my own analysis I often reference Tickeron's AI Daily Buy/Sell Signals for a systematic overlay. The platform applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals that reflect evolving market conditions, technical patterns, and data-driven insights. For a name like TMDX that has shown notable volatility, these automated signals can help track momentum shifts alongside the fundamental picture.

Final Assessment

The $100 central target, drawn from the average of current analyst estimates, lies roughly 31% above the latest price and represents a meaningful yet plausible advance. The supporting case built on transplant-volume growth and recurring revenue remains plausible, yet near-term earnings pressure, a premium forward valuation, and the wide dispersion of targets from $65 to $120 create real hurdles. Whether TMDX can reach $100 will depend largely on whether upcoming results and guidance restore confidence in the earnings trajectory. As with any high-beta growth-stage medical technology stock, outcomes remain uncertain and no single target should be treated as a firm prediction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Scott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking

Notable companies

Industry description

Market Cap

High and low price notable news

Volume